ACR Image Metrix hosted Novel Medical Imaging Approaches for Early Drug Development event

Oct 18 2010

ACR Image Metrix™, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, hosted the Novel Medical Imaging Approaches for Early Drug Development—Methods, Technical Issues and Case Studies event, which took place at the Boston Marriott Cambridge, in Cambridge Massachusetts, on September 16, 2010.

“Methodologic Considerations in Designing Pharmaceutical Trials Using Novel Imaging Methods.”

ACR Image Metrix is a leader in global imaging trials. Industry experts from ACR Image Metrix presented high caliber research on methods and technical issues related to clinical trials. Chief scientific officer, Bruce Hillman, M.D., FACR, of ACR Image Metrix, presented the topic, "Methodologic Considerations in Designing Pharmaceutical Trials Using Novel Imaging Methods." Scientific director of ACR Image Metrix' imaging core laboratory, Mehdi Adineh, Ph.D., presented "Increasing the Effectiveness of Novel Imaging in Clinical Trials: The Role of the Imaging Core Laboartory." Greg Sorenson, M.D., professor of radiology at Harvard Medical School, Massachusetts General Hospital, also presented his topic, "Mechanistic Imaging in Cancer Trials: Lessons from Glioblastoma."

"We [ACR Image Metrix] are the industry leader in global imaging trials," stated Dr. Hillman. "Our time put forth, dedication and determination, research and information access paves the way for innovation and drives the future of imaging in clinical trials."

As one of the industry's leading imaging CROs, ACR Image Metrix specializes in providing imaging CRO services to assist pharmaceutical, biotech and medical device companies around the world.